Single-use Bioreactors Market Size, Share Global Analysis Report, 2024 – 2032

Industry Insights

[208+ Pages Report] According to Facts and Factors, the global single-use bioreactors market size was valued at USD 3,400.65 million in 2023 and is predicted to surpass USD 4,456.50 million by the end of 2032. The single-use bioreactors industry is expected to grow by a CAGR of 3.05% between 2024 and 2032.

Market Overview

Single-use bioreactors are bioprocessing equipment crucial for the production of biological products like vaccines and biopharmaceuticals. These have become more popular in the biotechnology and biopharmaceutical industries due to their flexibility and scalability. Also, these are single-use materials as they are made up of disposable plastic. These bioreactors have a quick turnaround time and are cost-effective as compared to other available options in the market.

Key Insights

• As per the analysis shared by our research analyst, the global single-use bioreactors market size is estimated to grow annually at a CAGR of around 3.05% over the forecast period (2024-2032).
• In terms of revenue, the global single-use bioreactors market size was valued at around USD 3,400.65 million in 2023 and is projected to reach USD 4,456.50 million by 2032.
• Fast expansion of the biopharmaceutical sector is driving the growth of the global single-use bioreactors market.
• Based on the end-users, the indirect sales channel segment is growing at a high rate and is projected to dominate the global market.
• Based on the usage types, the lab-scale production segment is projected to swipe the largest market share.
• Based on the applications, the process development segment is expected to dominate the global market.
• Based on the molecule type, the vaccine segment is expected to witness significant growth in the global market.
• Based on region, North America is expected to dominate the global market during the forecast period.

Growth Drivers

• Fast expansion of the biopharmaceutical sector is driving the growth of the global market.

The biopharmaceutical sector is expected to see huge developments due to the growing commercialization of biotherapeutics like biologics, monoclonal antibiotics, and vaccines. However, the global marketplace is witnessing huge demand for efficient and flexible processing solutions, which are also expected to boost the growth of the global single-use bioreactors market. The single-use bioreactors are flexible and can easily be adapted to different production skills.

The single-use bioreactors also easily meet the requirements of biopharmaceutical companies. The disposable nature of these bioreactors reduces the risk of cross-contamination between the batches. Therefore, all these factors will contribute to the growth of the industry in the coming years. For instance, Pall Corporation and BioCentriq partnered with each other in July 2021 to produce Zolgensma. Zolgensma is an FDA-approved gene therapy.

Restraints

• Advancements in technologies are expected to foster growth opportunities in the global market.

The ongoing technological innovations in single-use bioreactors are expected to foster growth opportunities in the global single-use bioreactors market. Innovation in material and design contributes towards enhanced reliability, performance, and user-friendly features. Also, companies are investing in advanced technologies to scale up the efficiency of their processing operations.

For instance, Sartorius declared that it would invest in extending its capabilities in 2022 by building a new R&D unit with other required equipment to align with the surging demand from the biopharmaceutical sector.

Opportunities

• Material limitation is expected to hamper the growth of the global market.

Single-use bioreactors manufactured with plastic materials and the limitations associated with plastic are expected to restrict the growth of the single-use bioreactors industry. Various issues associated with materials, like extractability and leachability, further slow down the growth of the industry. Moreover, these bioreactors also have some limitations, particularly in scalability for high-volume production.

Challenges

• High upfront cost is a big challenge in the global market.

Single-use bioreactors are cost-effective in the long term, but the high initial investment as compared to traditional bioreactors is a big challenge in the global single-use bioreactors market. Moreover, process intensification has emerged as a challenge for single-use systems because its ability to handle high density may create problems.

Segmentation Analysis

The global single-use bioreactors market can be segmented into end-users, usage types, applications, molecules types, and regions.

By end-users, the market can be segmented into academic & research institutes, CROs & CMOs, and pharmaceutical & biopharmaceutical companies. The CROs and CMOs segment accounts for the largest share of the single-use bioreactors industry during the forecast period. The pharmaceuticals and biopharmaceutical companies outsource some of their production processes to CMOs and CROs. This trend of outsourcing is fostering demand in the segment.

Moreover, single-use bioreactors attract organizations because of their cost-effectiveness and flexibility. The single-use bioreactors help CROs and CMOs with scalability, thereby helping them deal with different clients with distinct production needs. Cost advantages associated with single-use bioreactors also align with the business model of CROs and CMOs. These organizations work on a contract basis and have faster turnaround times.

By usage type, the market can be segmented into large-scale production, pilot-scale production, and lab-scale production. The lab-scale production segment is projected to see huge developments in the forthcoming years. Lab scale is important during the early stages of the product development cycle. It helps organizations streamline their processes.

Also, the growing research and development activities led to the innovation of many vaccines, biopharmaceuticals, and biological products. Moreover, the lab scale is crucial in the biopharmaceuticals sector as the sector has a continuous pipeline of diverse products. All these factors are likely to foster growth opportunities in the segment.

By application, the market can be segmented into bioproduction and process development. The process development segment is likely to dominate the single-use bioreactors industry during the anticipated period. Process development is an essential step in establishing the processes during the early stages of biopharmaceutical development.

Also, product development helps in the rapid prototyping of production processes, thereby helping brands market their products efficiently in less time periods. Moreover, process development optimizes the different parameters like media formulations and cell culture conditions to ensure scalability and reproducibility.

Additionally, the growing emphasis on biologics like vaccines, gene therapy, etc., is significantly accentuating the demand for production development capabilities in the market. All these factors are anticipated to positively impact the growth trajectory of the segment during the forecast period.

By molecule type, the market can be segmented into stem cells, gene-modified cells, vaccines, monoclonal antibodies, and others. The vaccine segment is expected to witness significant growth during the forecast period. The growing health challenges like epidemics and infectious diseases are posing a huge demand for vaccines in the global marketplace. The COVID-19 pandemic has raised the demand for vaccines, thereby emphasizing the importance of scalable vaccine manufacturing in the market.

However, advancements in vaccines are also contributing to the increased demand for vaccines in the segment. Governments, organizations, and pharma companies are highly emphasizing the importance of disease preparedness, which is also expected to foster growth opportunities in the market.

Report Scope

Regional Analysis

• North America to dominate the global market.

North America accounts for the largest share of the global single-use bioreactors market during the forecast period. The fast expansion of the biopharmaceutical sector is one of the major factors for the high growth rate of the regional market. The growing need for biologics like gene therapy, vaccines, and many others boosts the adoption of single-use bioreactors in the region.

Moreover, the regulatory bodies in the region also encourage the use of single-use technology in bioprocessing, which in turn is also expected to support the growth trajectory of the regional market. The flexibility and cost-saving advantages offered by single-use bioreactors appeal to consumers and thereby facilitate their widespread adoption in North America. The biopharmaceutical and contract manufacturing organizations are making huge investments in upgrading their biomanufacturing facilities, which is also anticipated to support the growth of the regional market.

Europe is also expected to see major developments in the global single-use bioreactors market in the coming years. The region has a well-established biopharmaceutical sector, which is a major reason for the high growth rate of the regional market. There is a high demand for biochem and biologics, which in turn is boosting the requirements for flexible and efficient bioprocessing solutions like bioreactors.

Also, the regulatory landscape in the region is also expected to support single-use technologies and facilitate widespread adoption of single-use bioreactors in the region. Moreover, the single-use bioreactors are cost-effective, which resonates well with the growing companies in the region to optimize their manufacturing processes.

The single-use bioreactors are largely aligned with the sustainability goals, and therefore, companies in the region are looking forward to single-use bioreactors, thereby fostering growth in the regional market. Also, the collaborations between biopharmaceutical companies and technology vendors are facilitating innovation in the European market, which is also expected to pave the way for growth opportunities in the coming years. For instance, Thermo Fisher Scientific declared that it would build a new unit in September 2021 dedicated to single-use bioprocessing products in North America.

Competitive Analysis

The key players in the global single-use bioreactors market include:

• Biotech GmbH
• Stobbe Pharma GmbH
• Satake Chemical Equipment Mfg. Ltd.
• Solida Biotech GmbH
• G&G Technologies Inc.
• Able Corporation & Biott Corporation
• ABEC
• Distek Inc.
• PBS Biotech IncCellexus
• Eppendorf AG
• Getinge AB
• Celltainer Biotech BV
• Merck KgaA
• Thermo Fisher Scientific
• Sartorius Stedim Biotech

For instance, Logic Bio Therapeutics collaborated with Exothera SA in June 2022 to produce a highly scalable AVV manufacturing platform. Polyplus-transfection SA is also said to partner with these two.

The global single-use bioreactors market is segmented as follows:

By End-users Segment Analysis

• Academic & Research Institutes
• CROs & CMOs
• Pharmaceutical & Biopharmaceutical Companies

By Usage Types Segment Analysis

• Large-Scale Production
• Pilot-Scale Production
• Lab-Scale Production

By Applications Segment Analysis

• Bioproduction
• Process Development

By Molecules Types Segment Analysis

• Stem Cells
• Gene-Modified Cells
• Vaccines
• Monoclonal Antibodies
• Others

By Regional Segment Analysis

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America